Effectiveness of long-acting injectable antipsychotics: a clinical perspective
Open accessAbstract
The personal and societal costs of schizophrenia spectrum disorders are immense. Affected individuals may experience positive, negative and mood symptoms; medical and substance use comorbidities; and cognitive impairment that significantly impair social and occupational functioning. Globally, schizophrenia is a leading cause of years lost to disability, with a particularly large burden among adolescents and young adults.1 Treatment of schizophrenia spectrum disorders aims at improved functioning and recovery across the lifespan, but symptom reduction and relapse prevention are important interim goals. Although antipsychotic medications reduce psychotic symptoms and greatly decrease the risk of relapse, their effectiveness in real-world practice is decreased by non-adherence.2 A meta-analysis of studies that used trained personnel to measure antipsychotic medication adherence found that not ‘regularly taking medications as prescribed’ is prevalent in an average of 41% of participants across 10 studies.3 Despite this high prevalence, providers are often unaware of this issue and generally overestimate medication adherence in their patients.4 Long-acting injectable (LAI) formulations of antipsychotic medications were developed to improve adherence. The first LAIs, fluphenazine enanthate and decanoate, were introduced in 1966 in the context of large-scale deinstitutionalisation of patients with serious mental illnesses and the consequent need for effective community-based treatment. Numerous LAI antipsychotics have been developed and marketed in the meantime. Table 1 lists the LAI antipsychotic medications currently available in the USA and the UK.5 ,6 View this table: Table 1 Long-acting antipsychotic injectable medications available in the USA and the UK5 ,6 LAIs reduce the frequency at which a patient has to decide whether to take medication. Rather than deciding to take a medication once or twice daily, the patient must only decide to have an injection administered once or twice monthly. Pharmacokinetically, LAIs provide a more stable steady-state concentration of medication in the blood compared with daily oral …
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The fewer adverse ANS effects of long-acting injectable antipsychotics are likely due to different pharmacokinetic profiles, with a single injection once or twice a month providing a more steady state of antipsychotic in the blood than daily oral dosing.
“This finding is likely due to the different pharmacokinetic profiles of these drug formulations given that a single injection once or twice a month provides a more steady state of the AP in the blood than daily oral dosing would55.”
From Autonomic nervous system dysfunction in schizophrenia: impact on cognitive and metabolic health (2021) · cites this paper as [55]
Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., Samara, M., Barbui, C., Engel, R. R., Geddes, J. R., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60733-3 · Cited by 2,561 · see citing works
(1958) · Journal of the American Pharmaceutical Association (Scientific ed ) · doi:10.1002/jps.3030470133 · Cited by 2,491 · see citing works
Global burden of disease in young people aged 10–24 years: a systematic analysis
Gore, F. M., Bloem, P. J., Patton, G. C., Ferguson, J., Joseph, V., Coffey, C., Sawyer, S. M., & Mathers, C. D. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60512-6 · Cited by 2,301 · cited 1× · see citing works
“Globally, schizophrenia is a leading cause of years lost to disability, with a particularly large burden among adolescents and young adults.(1) Treatment of schizophrenia spectrum disorders aims at improved functioning and recovery across the lifespan, but symptom reduction and relapse prevention are important interim…”
BackgroundSecond-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C., & Davis, J. M. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61764-x · Cited by 1,930 · see citing works
Lacro, J. P., Dunn, L. B., Dolder, C. R., Leckband, S. G., & Jeste, D. V. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1007 · Cited by 1,383 · cited 1× · see citing works
“A meta-analysis of studies that used trained personnel to measure antipsychotic medication adherence found that not ‘regularly taking medications as prescribed’ is prevalent in an average of 41% of participants across 10 studies.(3) Despite this high prevalence, providers are often unaware of this issue and generally…”
BackgroundSecond-Generation (Atypical) Antipsychotics and Metabolic Effects
Newcomer, J. W. (2005) · CNS Drugs · doi:10.2165/00023210-200519001-00001 · Cited by 1,334 · see citing works
Jones, P., Barnes, T., Davies, L., Dunn, G., Lloyd, H., Hayhurst, K. P., Murray, R., Markwick, A., & Lewis, S. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.10.1079 · Cited by 1,060 · see citing works
Leucht, S., Tardy, M., Komossa, K., Heres, S., Kissling, W., Salanti, G., & Davis, J. M. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60239-6 · Cited by 931 · see citing works
Tiihonen, J., Haukka, J., Taylor, M., Haddad, P. M., Patel, M. X., & Korhonen, P. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10081224 · Cited by 619 · see citing works
Goff, D. C., Sullivan, L. M., McEvoy, J. P., Meyer, J. M., Nasrallah, H. A., Daumit, G. L., Lamberti, S., D'Agostino, R. B., Stroup, T. S., Davis, S., et al. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.08.010 · Cited by 528 · see citing works
Self-citationLeucht, C., Heres, S., Kane, J. M., Kissling, W., Davis, J. M., & Leucht, S. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2010.11.020 · Cited by 419 · see citing works
Kishimoto, T., Robenzadeh, A., Leucht, C., Leucht, S., Watanabe, K., Mimura, M., Borenstein, M., Kane, J. M., & Correll, C. U. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs150 · Cited by 395 · see citing works
Tiihonen, J., Wahlbeck, K., Lönnqvist, J. K., Klaukka, T., Ioannidis, J. P. A., Volavka, J., & Haukka, J. K. (2006) · BMJ · doi:10.1136/bmj.38881.382755.2f · Cited by 385 · see citing works
Rosenheck, R., Perlick, D., Bingham, S., Liu-Mares, W., Collins, J., Warren, S., Leslie, D., Allan, E., Campbell, E. C., Caroff, S., et al. (2003) · Journal of the American Medical Association (JAMA) · doi:10.1001/jama.290.20.2693 · Cited by 319 · see citing works
Arterial Stiffness and Stroke in Hypertension
Laurent, S., & Boutouyrie, P. (2005) · CNS Drugs · doi:10.2165/00023210-200519010-00001 · Cited by 236 · see citing works
Long-Acting Risperidone and Oral Antipsychotics in Unstable Schizophrenia
Rosenheck, R. A., Krystal, J. H., Lew, R., Barnett, P. G., Fiore, L. D., Valley, D., Thwin, S. S., Vertrees, J. E., & Liang, M. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1005987 · Cited by 213 · see citing works
Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets
Chue, P. S., Eerdekens, M., Augustyns, I., Lachaux, B., Molčan, P., Eriksson, L., Pretorius, H., & David, A. S. (2004) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2004.07.003 · Cited by 197 · see citing works
Kane, J. M., Detke, H. C., Naber, D., Sethuraman, G., Lin, D., Bergstrom, R. F., & McDonnell, D. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.07081221 · Cited by 196 · see citing works
Byerly, M., Fisher, R., Whatley, K., Holland, R., Varghese, F. P., Carmody, T. J., Magouirk, B., & Rush, A. J. (2005) · Psychiatry Research · doi:10.1016/j.psychres.2004.11.002 · Cited by 181 · see citing works
Efficacy and Effectiveness of Depot Versus Oral Antipsychotics in Schizophrenia
Kirson, N. Y., Weiden, P. J., Yermakov, S., Huang, W., Samuelson, T., Offord, S. J., Greenberg, P. E., & Wong, B. J. O. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12r08167 · Cited by 177 · see citing works
Antipsychotic Medication Adherence in Schizophrenia
Byerly, M., Nakonezny, P. A., & Lescouflair, E. (2007) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2007.04.002 · Cited by 177 · see citing works
McEvoy, J. P., Byerly, M., Hamer, R. M., Dominik, R., Swartz, M. S., Rosenheck, R. A., Ray, N., Lamberti, J. S., Buckley, P. F., Wilkins, T. M., et al. (2014) · JAMA · doi:10.1001/jama.2014.4310 · Cited by 151 · see citing works
Self-citationOlivares, J. M., Rodriguez-Morales, A., Diels, J., Povey, M., Jacobs, A., Zhao, Z., & Lam, A. (2009) · European Psychiatry · doi:10.1016/j.eurpsy.2008.12.002 · Cited by 141 · see citing works
Shi, L., Ascher‐Svanum, H., Zhu, B., Faries, D. E., Montgomery, W. S., & Marder, S. R. (2007) · Psychiatric Services · doi:10.1176/ps.2007.58.4.482 · Cited by 112 · see citing works
Rubio, G., Martínez, I., Ponce, G., Jiménez‐Arriero, M. Á., Lopez-Munoz, F. J., & Álamo, C. (2006) · The Canadian Journal of Psychiatry · doi:10.1177/070674370605100808 · Cited by 109 · see citing works
British national Formulary 1981
Wright, N. (1981) · Journal of Hospital Infection · doi:10.1016/0195-6701(81)90036-0 · Cited by 104 · see citing works
Equivalent Switching Dose From Oral Risperidone to Risperidone Long-Acting Injection
Bai, Y. M., Chen, T. T., Chen, J. Y., Wu, W.-H., Hung, C. H., & Lin, W. K. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0808 · Cited by 91 · see citing works
Keks, N. A., Ingham, M., Khan, A., & Karcher, K. (2007) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.105.017020 · Cited by 83 · see citing works
Arango, C., Bombín, I., González-Salvador, T., García‐Cabeza, I., & Bobes, J. (2005) · European Psychiatry · doi:10.1016/j.eurpsy.2005.07.006 · Cited by 82 · see citing works
Comparison of SGA Oral Medications and a Long-Acting Injectable SGA: The PROACTIVE Study
Buckley, P. F., Schooler, N. R., GOFF, D. C., Hsiao, J., Kopelowicz, A. J., Lauriello, J., Manschreck, T. C., Mendelowitz, A. J., Miller, D. D., Severe, J. B., et al. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu067 · Cited by 72 · see citing works
Zhu, B., Ascher‐Svanum, H., Shi, L., Faries, D. E., Montgomery, W. S., & Marder, S. R. (2008) · Psychiatric Services · doi:10.1176/ps.2008.59.3.315 · Cited by 66 · see citing works
Covell, N. H., McEvoy, J. P., Schooler, N. R., Stroup, T. S., Jackson, C. T., Rojas, I. A., Essock, S. M., & Schizophrenia Trials Network (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.11m07074 · Cited by 50 · see citing works
Self-citationHaro, J. M., Novick, D., Belger, M., & Jones, P. B. (2006) · European Psychiatry · doi:10.1016/j.eurpsy.2005.12.001 · Cited by 49 · see citing works
Long-Acting Injectable Risperidone
Ehret, M. J., & Fuller, M. A. (2004) · Annals of Pharmacotherapy · doi:10.1345/aph.1e085 · Cited by 48 · see citing works
The increase in risk of diabetes mellitus from exposure to second-generation antipsychotic agents.
Citrome, L. (2004) · Drugs of Today · doi:10.1358/dot.2004.40.5.850492 · Cited by 47 · see citing works
Chouinard, G., Annable, L., & STEINBERG, S. (1986) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198602000-00005 · Cited by 31 · see citing works
Brnabic, A. J. M., Kelin, K., Ascher‐Svanum, H., Montgomery, W. S., KADZIOLA, Z. A., & Karagianis, J. L. (2011) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2011.02743.x · Cited by 28 · see citing works
Gäebel, W., & Zielasek, J. (2012) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2011.01819.x · Cited by 23 · see citing works
Lammers, L., Zehm, B., & Williams, R. L. (2013) · BMC Psychiatry · doi:10.1186/1471-244x-13-155 · Cited by 18 · see citing works
Maintenance treatment with long-acting injectable antipsychotics: comparing old with new.
Goff, D. (2014) · Journal of the American Medical Association (JAMA) · doi:10.1001/jama.2014.4311 · Cited by 11 · see citing works
Noninferiority of Perphenazine vs. Three Second-Generation Antipsychotics in Chronic Schizophrenia
Rosenheck, R., & Lin, H.-Q. (2014) · Journal of Nervous and Mental Disease · doi:10.1097/nmd.0000000000000065 · Cited by 11 · see citing works
(2011) · Medical Entomology and Zoology · Cited by 10 · see citing works
Self-citation
Flagged first, then by citations
1 of the 43 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Autonomic nervous system dysfunction in schizophrenia: impact on cognitive and metabolic health
Stogios, N., Gdanski, A., Gerretsen, P., Chintoh, A. F., Graff-Guerrero, A., Rajji, T. K., Remington, G., Hahn, M. K., & Agarwal, S. M. (2021) · npj Schizophrenia · doi:10.1038/s41537-021-00151-6 · Cited by 98 · see citing works
Moledina, A., Magwood, O., Agbata, E. N., Hung, J., Saad, A., Thavorn, K., Salvalaggio, G., Bloch, G. C., Ponka, D., Aubry, T., et al. (2021) · Campbell Systematic Reviews · doi:10.1002/cl2.1154 · Cited by 57 · see citing works
Long-Acting Injectable Antipsychotics—A Review on Formulation and In Vitro Dissolution
Markowicz-Piasecka, M., Kubisiak, M., Asendrych-Wicik, K., Kołodziejczyk, M. K., Grzelińska, J., Fabijańska, M., & Pietrzak, T. M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics16010028 · Cited by 47 · see citing works
“…between the results of different meta-analyses might stem from several factors, such as changes over the years in the definition of relapse, dissimilarities between older and newer neuroleptics, patient selection, and recent current trends towards the use of lower doses of neuroleptics [34].”
ResultLorenzo, R. D., Ferri, P., Cameli, M., Rovesti, S., & Piemonte, C. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s189245 · Cited by 36 · see citing works
“The first LAI-APD, fluphenazine decanoate, was put on the market in 1966 in the historical context of large-scale deinstitutionalization and a consequent need for effective community treatments.(15) Over the years, other LAI-APDs were developed from the so-called first-generation APDs (FGAs) through esterification of…”
BackgroundAttitudes of European physicians towards the use of long-acting injectable antipsychotics
Patel, M. X., Bent‐Ennakhil, N., Sapin, C., di Nicola, S., Loze, J.-Y., Nylander, A.-G., & Heres, S. (2020) · BMC Psychiatry · doi:10.1186/s12888-020-02530-2 · Cited by 40 · see citing works
“elimination of bias through patient randomization), which may minimize differences between LAI and oral formulations that would otherwise manifest in clinical practice [7, 22].”
BackgroundInfluentialCurrent and emerging long-acting antipsychotics for the treatment of schizophrenia
de Filippis, R., Fazio, P. D., Gaetano, R., Steardo, L., Cedro, C., Bruno, A., Zoccali, R., & Muscatello, M. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1910674 · Cited by 43 · see citing works
Park, C., Lee, H., Oh, D., Kang, J., Han, C.-S., & Kim, D. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s151437 · Cited by 36 · see citing works
“Currently, some antipsychotic drugs are being developed in a similar manner, such as Abilify Maintena (aripiprazole monohydrate), Zyprexa Relprevv (olanzapine pamoate), and Invega Trinza (paliperidone palmitate), which are available in the US and in the UK.(10) Long-acting antipsychotic formulations can avoid the firs…”
BackgroundLlorca, P., Bobes, J., Fleischhacker, W. W., Heres, S., Moore, N. D., Bent‐Ennakhil, N., Sapin, C., Loze, J.-Y., Nylander, A., & Patel, M. X. (2018) · European Psychiatry · doi:10.1016/j.eurpsy.2018.04.004 · Cited by 25 · see citing works
Increasing placebo response in antipsychotic trials: a clinical perspective
Dold, M., & Kasper, S. F. (2015) · Evidence-Based Mental Health · doi:10.1136/eb-2015-102098 · Cited by 14 · see citing works
“With regard to antipsychotic drugs, for example, it is crucial to consider this phenomenon, especially when evaluating the effectiveness of long-acting injectable (LAI) formulations in schizophrenia.(15) The less severely ill patients incorporated usually in blinded RCTs mitigate the chances for revealing a superiorit…”
Lindskog, U., Lundgren, B., Billig, D., & Lindner, E. (1987) · PubMed · Cited by 10 · see citing works
Do Long-Acting Injectable Antipsychotics Prevent or Delay Hospital Readmission?
Maestri, T. J., Mican, L. M., Rozea, H., & Barner, J. C. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4571 · Cited by 10 · see citing works
Gundugurti, P. R., Nagpal, R., Sheth, A., Narang, P., Gawande, S., & Singh, V. (2017) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2017.08.002 · Cited by 9 · see citing works
Fan, S.-J., Lü, N., Chang, H.-C., Tang, C., & Huang, K.-C. (2018) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000213 · Cited by 6 · see citing works
“…abuse associated with schizophrenia, cognitive impairment, severe symptoms, lack of insight into illness, and history of medication nonadherence as patients would be followed up if they miss their injection appointments (Johnson and Freeman, 1973; Castillo and Stroup, 2015; Subotnik et al., 2015).”
Challenges in psychopharmacology: a drug information centre perspective
Schjøtt, J. D. (2016) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12354 · Cited by 5 · see citing works
“Long-acting injectable depot formulations (LAI) of antipsychotics are popular, and they are useful in the care of chronic psychiatric patients, particularly those show low adherence to prescribed therapy or who are not institutionalized.(25) The slow release and absorption of active drug from the injection site make t…”
BackgroundFluphenazine decanoate‐induced bradycardia: A case report
Kamali, M., Zarghami, M., Azizi, M., & Elyasi, F. (2022) · Neuropsychopharmacology Reports · doi:10.1002/npr2.12251 · Cited by 5 · see citing works
The Role of Long-Acting Injectable Antipsychotics in the Early Treatment of Schizophrenia
Harrison, S. J., Antunes, J., Knight, K., Johnston, K., Mehawej, J., Sanchez, P., & Correll, C. U. (2026) · CNS Drugs · doi:10.1007/s40263-026-01294-9 · Cited by 3 · see citing works
“Attitudes of health professionals towards LAIs have been identified as playing a crucial role in whether patients take antipsychotics [53, 147, 148].”
Ibrahim, H. (2021) · Federal Practitioner · doi:10.12788/fp.0195 · Cited by 3 · see citing works
Paliperidone Palmitate Treatment in Outpatient Care Setting: A Naturalistic Study.
Lorenzo, R. D., Cameli, M., Bolondi, M., Landi, G., Moretti, V., Piemonte, C., & Pollutri, G. (2016) · Psychopharmacology bulletin · doi:10.64719/pb.4341 · Cited by 3 · see citing works
Berardi, L., Antonazzo, I. C., Piccinni, C. P., Raschi, E., Forcesi, E., Fioritti, A., Berardi, D., Ponti, F. D., Piazza, A., & Poluzzi, E. (2019) · PLoS ONE · doi:10.1371/journal.pone.0211938 · Cited by 3 · see citing works
Şizofrenide Uzun Etkili Enjektabl Antipsikotik Tedaviye Geçişin Bakım Yükü Üzerine Etkisi
Tozoğlu, E. Ö., & Özpolat, G. (2021) · Psikiyatride Guncel Yaklasimlar - Current Approaches in Psychiatry · doi:10.18863/pgy.991538 · Cited by 2 · see citing works
Long-acting injectable risperidone as an option in first-episode psychosis
Covell, N. H. (2016) · Evidence-Based Mental Health · doi:10.1136/eb-2015-102207 · Cited by 1 · see citing works
Dold, L. B. M., & Praschak-Rieder, N. (2015) · Journal of Clinical Toxicology · doi:10.4172/2161-0495.1000270 · Cited by 1 · see citing works
“Long-acting injectable (LAI) antipsychotics are increasingly appreciated in the course of maintenance treatment of schizophrenia playing an important role in improving adherence and preventing hospitalizations [1].”
BackgroundPharmacology and Psychopharmacology
Tampi, R. R., Tampi, D. J., & Lavakumar, M. (2018) · Springer eBooks · doi:10.1007/978-3-319-73078-3_25 · Cited by 1 · see citing works
Aripiprazole Long-Acting Injections Improved Control of Parkinson's Disease
Her, Y., Chen, C., Chang, H., Kao, Y., Wan, F.-J., & Tzeng, N. (2020) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001269 · Cited by 1 · see citing works
Frühbehandlung bei psychotischen Erkrankungen mit Depotantipsychotika
Herz, R., & Czelecz, A. (2015) · psychopraxis neuropraxis · doi:10.1007/s00739-015-0286-6
Takekita, Y., & Serretti, A. (2016) · Evidence-Based Mental Health · doi:10.1136/eb-2015-102215
“WHAT IS ALREADY KNOWN ON THIS TOPIC? Depot antipsychotics may increase adherence to medication, reducing recurrence and rehospitalisation in schizophrenia.(1) Aripiprazole lauroxil, a novel lipid ester prodrug of aripiprazole, is a long-acting injection (LAI) administered intramuscularly.”
BackgroundLong-Acting Injection for Psychotic Disorder
Mauri, M., & Pace, C. D. (2018) · Clinical Cases in Psychiatry: Integrating Translational Neuroscience Approaches · doi:10.1007/978-3-319-91557-9_14
Tozoğlu, E. Ö., & Özpolat, G. (2021) · Research Square · doi:10.21203/rs.3.rs-371364/v1
- Authors
- Castillo, E. G., & Stroup, T. S.
- Affiliations
- Columbia University Irving Medical Center (US)
- Corresponding author
- Stroup, T Scott
- Venue
- Evidence Based Mental Health
- Publisher
- BMJ
- Published
- 2015-04-08
- Volume
- 18
- Issue
- 2
- Pages
- 36-39
- ISSN
- 1362-0347 (ISSN-L)
- 1468-960X
- PMC
- PMC11234955
- OpenAlex
- W2171715667
- Cited by
- 28
- References
- 43
- Citations by year
- 2026: 1 · 2025: 2 · 2023: 1 · 2022: 1 · 2021: 6 · 2020: 2 · 2019: 2 · 2018: 5 · 2017: 1 · 2016: 3 · 2015: 3
- FWCI
- 3.24
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Evidence-Based Mental Health (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Keywords
- long-acting injectable antipsychotics, schizophrenia spectrum disorders, medication adherence, relapse prevention, fluphenazine, decanoate, deinstitutionalization, community-based treatment, pharmacokinetics, treatment effectiveness
- MeSH terms
- Administration, Oral, Delayed-Action Preparations, Humans, Injections, Schizophrenia, Antipsychotic Agents, Medication Adherence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
